Search
Fennec Pharmaceuticals Inc
FENCAdd to Watchlist
10.700USD
+0.360+3.48%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
369.59MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+3.48%
5 Days
-2.90%
1 Month
+16.81%
6 Months
+39.32%
Year to Date
+38.96%
1 Year
+21.59%
Key Figures
10.350Open
10.880High
140.51KVolume
LossP/E TTM
11.64P/E Dynamic
--Dividend TTM
0.41%Turnover Ratio
10.340Prev. Close
10.300Low
1.22MTurnover
LossP/E Static
9.81P/B
0.00%Div Yield TTM
-14.17%ROA
9.92052wk High
0.59Volume Ratio
-436.00KNet Profit
34.54MShares
-0.2928EPS TTM
0.97Beta
-52.68%ROE
4.68052wk Low
5.61%Amplitude
96.23%Gross Margin
369.59MMarket Cap
3.40Reward/Risk
3.79%Risk Rate
TradingKey Stock Score of Fennec Pharmaceuticals Inc
Currency: USD Updated: 2026-07-02Key Insights
Fennec Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 46 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.67.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Fennec Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Fennec Pharmaceuticals Inc Highlights
StrengthsRisks
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 110.06% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 44.64M.
Undervalued
The company’s latest PE is -36.55, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 18.57M shares, increasing 5.46% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 109.33K shares of this stock.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
15.667
Target Price
+51.52%
Upside Space
Fennec Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Fennec Pharmaceuticals Inc Info
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Ticker SymbolFENC
CompanyFennec Pharmaceuticals Inc
CEOHackman (Jeffrey S)
Websitehttps://fennecpharma.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Fennec Pharmaceuticals Inc (FENC)?
The current price of Fennec Pharmaceuticals Inc (FENC) is 10.70.
What is the symbol of Fennec Pharmaceuticals Inc?
The ticker symbol of Fennec Pharmaceuticals Inc is FENC.
What is the 52-week high of Fennec Pharmaceuticals Inc?
The 52-week high of Fennec Pharmaceuticals Inc is 9.92.
What is the 52-week low of Fennec Pharmaceuticals Inc?
The 52-week low of Fennec Pharmaceuticals Inc is 4.68.
What is the market capitalization of Fennec Pharmaceuticals Inc?
The market capitalization of Fennec Pharmaceuticals Inc is 365.54M.
Is Fennec Pharmaceuticals Inc (FENC) currently rated as Buy, Hold, or Sell?
According to analysts, Fennec Pharmaceuticals Inc (FENC) has an overall rating of Buy, with a price target of 15.67.
What is the Earnings Per Share (EPS TTM) of Fennec Pharmaceuticals Inc (FENC)?
The Earnings Per Share (EPS TTM) of Fennec Pharmaceuticals Inc (FENC) is -0.34.